Meeting Details - The fifth meeting of the Supervisory Board of Beijing Saiseng Pharmaceutical Co., Ltd. was held on June 19, 2025, with all three attending supervisors present [1][2] - The meeting was legally convened in accordance with relevant laws and regulations [1] Resolutions Passed - The Supervisory Board approved the proposal regarding the signing of a "New Drug Technology Transfer Contract" and related transactions [1][2] - The board confirmed that the transaction is necessary for the company's normal operations and aligns with its development strategy [2] Compliance and Impact - The Supervisory Board concluded that the transaction complies with legal and regulatory requirements and does not affect the company's independence or harm the interests of shareholders, particularly minority shareholders [2]

Core Viewpoint - The company has signed a new drug technology transfer contract with its affiliate, with a total transaction amount of 20 million yuan [1] Group 1: Transaction Details - The company has entered into a technology transfer agreement for the NeoAB33 new drug project with its affiliate, Huada Protein, for a total of 20 million yuan [1] - The transaction is classified as a related party transaction due to the involvement of the company's chairman, general manager, and chief engineer in Huada Protein's management [1] Group 2: Strategic Implications - The acquisition of the relevant technology will accelerate the development of the company's protein/antibody drug platform, enhancing its capabilities from molecular design to cell line construction [1] - The company aims to expand its pipeline reserves in the cardiovascular field, promoting a differentiated competitive layout in this niche market and accelerating the transformation of research and development results [1]

证券代码：300485 证券简称：赛升药业 公告编码：2025-025 北京赛升药业股份有限公司 关于签订《新药技术转让合同》暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 基于业务发展需要，北京赛升药业股份有限公司（以下简称"公司"或 "甲方"）与参股公司北京华大蛋白质研发中心有限公司（以下简称"华大蛋 白"或"乙方"）签署《新药技术转让合同》，华大蛋白将其拥有的NeoAB33新 药项目相关技术转让给公司，交易总额为2,000万元。 鉴于公司持有华大蛋白27.89%股权，公司董事长兼总经理马骉先生担任华 大蛋白的董事，公司总工程师孔双泉先生担任华大蛋白的董事，公司董事尹长 城先生担任华大蛋白董事兼总经理，根据《深圳证券交易所创业板股票上市规 则》，本次公司与华大蛋白签订《新药技术转让合同》构成关联交易。 公司于 2025 年 6 月 19 日召开了第五届董事会第八次会议及第五届监事会 第八次会议，审议通过了《关于签订<新药技术转让合同>暨关联交易的议案》。 董事会上，关联董事马骉、马丽、尹长城回避表决，全体独立董事表决同意 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-024 北京赛升药业股份有限公司 第五届监事会第八次会议决议公告 三、备查文件 第五届监事会第八次会议决议 北京赛升药业股份有限公司（以下简称"公司"）第五届监事会第八次会议 于 2025 年 6 月 19 日在公司会议室召开，本次会议于 2025 年 6 月 13 日以通讯的 方式向所有监事送达了会议通知。会议应参会监事 3 人，实际参会监事 3 人，公 司董事会秘书列席会议。会议由监事会主席赵丽娜女士主持。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体监事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 经审核，监事会认为：本次关联交易系公司正常经营需要，符合公司发展战 略，决策程序符合相关法律、法规及公司章程的规定，不会对公司的独立性造成 影响，不存在损害公司及股东利益，特别是中 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-023 北京赛升药业股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第八次会议 于2025年6月19日在公司会议室召开，本次会议于2025年6月13日以通讯的方式向 所有董事送达了会议通知。会议应参会董事8人，实际参会董事8人，会议由董事 长马骉先生主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 审议通过《关于签订〈新药技术转让合同〉暨关联交易的议案》 本议案具体内容详见发布于中国证监会指定的创业板信息披露网站的《关于 签订<新药技术转让合同>暨关联交易的公告》。 特此公告。 北京赛升药业股份有限公司 董 事 会 2025 年 6 月 20 日 公司独立董事专门会议审议通过了本议案。 表决结果 ...

Core Viewpoint - The company has signed a technology transfer agreement with its affiliate, BGI Protein, for the NeoAB33 new drug project, with a total transaction amount of 20 million yuan, which constitutes a related party transaction [1] Group 1: Transaction Details - The transaction involves the transfer of detailed technical materials, technical details, and related documents for the NeoAB33 project, including constructed cell lines and related research, characterization analysis, preliminary pharmaceutical and immunological studies, initial process research, and preliminary quality research technical materials, along with all original records in both written and electronic formats [1] - The agreement is based on an assessment result, ensuring that the pricing is fair and reasonable after sufficient communication between the parties involved [1] Group 2: Strategic Implications - This transaction will help the company accelerate the construction of its protein/antibody drug platform, expand its pipeline reserves in the cardiovascular field, and promote differentiated competitive layout in this niche market [1] - The agreement is expected to facilitate the transformation of research and development results, achieve technological complementarity and resource integration, and support the improvement of the company's innovative drug research and development system and market competitiveness [1]

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [7][24]. Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.40% from June 9 to June 13, 2025, outperforming the CSI 300 by 1.65 percentage points [2][12]. - Year-to-date, the Shenwan Pharmaceutical Bio Index has increased by 9.33%, surpassing the CSI 300 by 11.13 percentage points, ranking 4th among 31 Shenwan primary industry indices [2][14]. - As of June 13, 2025, the valuation of the pharmaceutical sector stands at 28.29 times (TTM overall method, excluding negative values), with a valuation premium of 153.19% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector has outperformed the CSI 300 index, ranking 5th among 31 primary industry indices during the specified period [2][12]. - The sector's valuation reflects a significant premium over the broader market, indicating strong investor interest [2][17]. 2. Important Events - On June 13, 2025, a State Council meeting emphasized the need for enhanced evaluation of drug and consumable procurement policies, aiming for a more standardized and institutionalized approach to procurement [4][21]. - The meeting also highlighted the importance of improving public hospital compensation mechanisms and supporting pharmaceutical companies in enhancing innovation capabilities [4][21]. 3. Industry Perspective - The report notes that the procurement process in China's pharmaceutical sector has been ongoing for nearly a decade, expanding from solid oral formulations to include various drug categories and medical devices [5][22]. - There is a positive outlook for innovative drugs, overseas expansion, and sectors where procurement impacts have been cleared, suggesting potential growth opportunities [5][22]. - The report encourages attention to specific segments such as insulin and orthopedics, as well as certain generic drug companies, due to the ongoing acceleration of procurement processes [5][22].

Market Overview - The ChiNext Index fell by 1.17%, closing at 2037.27 points, with a total trading volume of 411.80 billion yuan, an increase of 43.55 billion yuan compared to the previous trading day [1] - Among the tradable ChiNext stocks, 316 stocks closed higher, with 18 stocks rising over 10%, including Huaye Spice, Saiseng Pharmaceutical, and Zhongke Magnetic Materials, which hit the daily limit [1] Trading Activity - The average turnover rate for ChiNext stocks today was 4.56%, with 60 stocks having a turnover rate exceeding 20% [1] - The stock with the highest turnover rate was Kangliyuan, which closed up 13.17% with a turnover rate of 78.20% and a trading volume of 760 million yuan [1] - Other notable stocks with high turnover rates included Zhongke Magnetic Materials (59.04% turnover rate) and Guokang Biochemical (56.79% turnover rate) [1] Institutional Activity - Among the high turnover stocks, 11 were listed on the Dragon and Tiger List, indicating significant institutional trading activity [2] - Notable net purchases by institutions included Jinjiji Co. with a net buy of 58.05 million yuan and Fuchun Co. with a net buy of 48.92 million yuan [2] Fund Flow - In terms of fund flow, 33 high turnover stocks experienced net inflows, with the highest being Zhongwen Online (560 million yuan) and Fuchun Co. (221 million yuan) [3] - Conversely, the stocks with the largest net outflows included Runxin Technology (308 million yuan) and Hanyu Pharmaceutical (295 million yuan) [3] Performance of Specific Stocks - Kangliyuan and Zhongke Magnetic Materials were among the top performers, with significant price increases and high turnover rates [4] - Guokang Biochemical and Hailin Pharmaceutical faced notable declines, with Guokang Biochemical down by 10.32% [4][5] - The performance of new stocks like C Youyou, which had a turnover rate of 48.68%, was also highlighted [2]

Core Insights - The recombinant protein sector saw a rise of 1.42%, ranking 8th among concept sectors, with 26 stocks increasing in value, including Sai Sheng Pharmaceutical which hit a 20% limit up [1] - Major gainers in the sector included Jie Ya Co., Yi Pin Hong, and Zhong Yuan He He, with increases of 14.83%, 9.40%, and 6.85% respectively [1] - The sector experienced a net outflow of 223 million yuan in capital, with 13 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflows [2] Stock Performance - Sai Sheng Pharmaceutical led the net inflow with 165 million yuan, followed by Zhong Yuan He He, Ke Xing Pharmaceutical, and Yi Pin Hong with net inflows of 62.43 million yuan, 36.45 million yuan, and 28.04 million yuan respectively [2][3] - The top stocks by net inflow ratio included Sai Sheng Pharmaceutical at 23.69%, *ST Su Wu at 11.75%, and Ke Xing Pharmaceutical at 9.86% [3] Market Trends - The recombinant protein sector's performance was contrasted by other sectors, with the transgenic sector leading with a 3.15% increase, while EDR concept saw a decline of 2.63% [2] - The overall market sentiment reflected a mixed performance across various sectors, indicating selective investor interest [2]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ A股三大股指6月10日开盘涨跌互现。早盘指数分化，沪指在银行股走强下表现较强。午后两市快速下 挫，沪指更是一度跌1%。 从盘面上看，TMT行业全线调整，半导体、算力、AI应用、金融科技、消费电子概念股跌幅靠前。离 境退税、稀土永磁、种业题材午后逆势上涨；新消费、创新药概念股活跃。 至收盘，上证综指跌0.44%，报3384.82点；科创50指数跌1.47%，报982.9点；深证成指跌0.86%，报 10162.18点；创业板指跌1.17%，报2037.27点。 Wind统计显示，两市及北交所共1260只股票上涨，4034只股票下跌，平盘有118只股票。 沪深两市成交总额14153亿元，较前一交易日的12864亿元增加1289亿元。其中，沪市成交5574亿元，比 上一交易日5119亿元增加455亿元，深市成交8579亿元。 两市及北交所共有79只股票涨幅在9%以上，10只股票跌幅在9%以上。 计算机板块领跌两市，退市龙宇（维权）（603003）跌超30%，新致软件（688590）、中科信息 （300678）、慧博云通（301316）、石基信 ...